Clinical Trials
27 trialsIFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
Affiliated Hospital of Jiangnan University
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
University of California, Davis
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
Shanxi Bethune Hospital
SBRT Plus vNKT for Pancreatic Cancer
Changhai Hospital
Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma
Ruijin Hospital
A Study of RD14-01 in Patients With Advanced Solid Tumors
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
EBV CAR-T Cells for Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
ImmunoBreast - A Phase Ib Study
Odense University Hospital
NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer
The Third Affiliated Hospital of Guangzhou Medical University
Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
Xuanwu Hospital, Beijing
Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions
Zhejiang University
GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Affiliated Hospital to Academy of Military Medical Sciences
Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors
The Sixth Affiliated Hospital of Wenzhou Medical University
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）
The First Affiliated Hospital of Soochow University
CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS
Zhejiang University
ISIKOK-19
Acibadem University
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
The First Affiliated Hospital of Guangdong Pharmaceutical University
CARTEPC
First Affiliated Hospital of Chengdu Medical College
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
The Second Hospital of Nanjing Medical University
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
National University Hospital, Singapore
CART33
Chinese PLA General Hospital
CART-138
Chinese PLA General Hospital